Focus: Baxter International is a $10.4B global medical device and biopharmaceutical company headquartered in Deerfield, IL, serving critical care, renal, and nutritional markets with 50,000+ employees.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Hot — 246 jobs added in 30d
Net +40 (246 new, 206 removed). Aggressive expansion phase.
Baxter offers operational stability and scale for career growth in medical devices and critical care, but limited cutting-edge drug development opportunities for pipeline-focused professionals.
Next-generation dialysis filter representing Baxter's core renal care market focus.
Help build intelligence for Baxter International
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Baxter International's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Peritoneal dialysis solution anchoring Baxter's dominance in home-based renal replacement therapy.
Lipid emulsion for critical care nutrition, representing established revenue stream in parenteral therapy.
8-K Filing: HOLOGIC INC (HOLX) (CIK 0000859737) — EX-99.1
EX-99.1
8-K Filing: Inogen Inc (INGN) (CIK 0001294133) — EX-99.1
EX-99.1
Baxter International stock faces pressure from ifosfamide shortage and reduced production capacity a - AD HOC NEWS
Baxter International stock faces pressure from ifosfamide shortage and reduced production capacity a AD HOC NEWS
8-K Filing: BAXTER INTERNATIONAL INC (BAX) (CIK 0000010456) — 8-K
8-K
Tom Polen, 35 - Crain's Chicago Business
Tom Polen, 35 Crain's Chicago Business
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Jazz Pharmaceuticals (JAZZ) and Baxter International (BAX) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Jazz Pharmaceuticals (JAZZ) and Baxter International (BAX) The Globe and Mail
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Operational challenges in specific product lines (ifosfamide) suggest targeted restructuring risk rather than broad workforce reductions.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo